F2G and Shionogi released positive Phase III results for olorofim, an orally administered antifungal developed as a potential alternative to intravenous Ambisome for refractory aspergillosis. The study supported noninferiority versus I.V.-administered amphotericin B in patients with refractory disease or those unsuitable for azole therapy. The Phase III program, conducted under a long development arc after a prior FDA complete response letter, reported all-cause mortality at day 42 of 23.8% for olorofim versus 24.3% for Ambisome. The companies previously framed olorofim as a way to move away from IV administration while maintaining outcomes. The update matters for the broader antifungal market because the pipeline has been thin for novel oral options in invasive fungal disease. It also strengthens the resubmission logic for regulatory re-engagement. Analysts will likely focus on safety tolerability and how the oral route affects hospitalization patterns and care delivery.